 Purpose : Recent therapeutic trials evaluating immunosuppressive and biotherapy cyclophosphamide, mycophenolate mofetil, rituximab, belimumab in the field of immunologic and inflammatory diseases have found a risk of severe infection of 7 to 18 during the first year after the beginning of the treatment. Thus, the main objective of the study is to describe the incidence and risk-factors for infections in people treated with such agents for immunologic and inflammatory diseases. 